The following side effects were noted under treatment with<unk>  and heparin (and aspirin, if tolerated). Other drugs were used as necessary. The major adverse effect is bleeding on local sites of clinical intervention and systemically (regarding parts of the body or the whole body system). Major bleeding has occurred in 1.4% of patients and minor bleeding in 10.5%. Transfusions were required to terminate bleeding and to improve bleeding-related anemia in 4.0% of all patients. Geriatric patients have experienced more bleeding episodes than younger, women more than men. Thrombocytopenia was more often seen in the<unk>  + heparin group (1.5%) than in the heparin control group (0.8%). This adverse effect was usually readily reversible within days. Positive fecal and urine hemoglobin tests have also been reported. Post-marketing events have been the occurrence of intracranial bleeding, retroperitoneal bleeding, pulmonary hemorrhage and spinal-epidural hematoma. Fatal bleeding have been reported rarely. Sometimes, thrombocytopenia was associated with chills, low-grade fever or bleeding complications (see above). Cases of hypersensitivity including anaphylaxis have occurred.
Tirofiban
Tafamidis
Clopidogrel
Ticagrelor
Ticlopidine
Eptifibatide
Clofibride
Cetrorelix